Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
Novavax said it would co-commercialise its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.
